Brokerages Set Phibro Animal Health Corporation (NASDAQ:PAHC) Price Target at $42.50

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) have earned a consensus recommendation of “Hold” from the five analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $42.50.

A number of equities research analysts have issued reports on the stock. Zacks Research cut shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Citigroup cut their price target on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Weiss Ratings cut Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Finally, Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th.

Phibro Animal Health Price Performance

PAHC opened at $34.04 on Tuesday. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 0.47 and a beta of 0.46. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. The firm has a 50-day moving average price of $32.46 and a 200-day moving average price of $43.32. Phibro Animal Health has a twelve month low of $25.58 and a twelve month high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.04. The company had revenue of $383.54 million for the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Equities analysts expect that Phibro Animal Health will post 3.08 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd were issued a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend was Wednesday, June 3rd. Phibro Animal Health’s payout ratio is presently 20.60%.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 4,528 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $48.49, for a total transaction of $219,562.72. Following the sale, the chief executive officer directly owned 56,152 shares in the company, valued at $2,722,810.48. This represents a 7.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,648 shares of company stock worth $1,377,432 in the last quarter. Corporate insiders own 50.13% of the company’s stock.

Hedge Funds Weigh In On Phibro Animal Health

Hedge funds have recently bought and sold shares of the company. Cetera Investment Advisers increased its position in shares of Phibro Animal Health by 2.7% in the first quarter. Cetera Investment Advisers now owns 10,997 shares of the company’s stock worth $608,000 after purchasing an additional 293 shares during the last quarter. 1620 Investment Advisors Inc. lifted its position in Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares during the last quarter. Tudor Investment Corp ET AL lifted its position in Phibro Animal Health by 3.4% during the third quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after purchasing an additional 338 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Phibro Animal Health by 2.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after buying an additional 363 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after buying an additional 386 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.